Phoenix Biotechnology, Inc. – Trademark Portfolio
Entity Type: 03
Phoenix Biotechnology, Inc. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include PHOENIX BIOTECHNOLOGY and PHOENIX BIOTECHNOLOGY, INC.. The owner is based in San Antonio, TX.
8626 Tesoro Drive, Suite 801
San Antonio, TX 78217
Showing of trademarks Trademarks
Trademark Classifications
Phoenix Biotechnology, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Phoenix Biotechnology, Inc. have?
Phoenix Biotechnology, Inc. has 6 U.S. trademarks filed with the USPTO. Of these, 2 registered, 4 abandoned.
What trademark classes does Phoenix Biotechnology, Inc. file in?
Phoenix Biotechnology, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Phoenix Biotechnology, Inc.'s most well-known trademarks?
Phoenix Biotechnology, Inc.'s registered trademark portfolio includes well-known marks such as PHOENIX BIOTECHNOLOGY and PHOENIX BIOTECHNOLOGY, INC.. These are among 2 currently registered trademarks in the portfolio.
What is Phoenix Biotechnology, Inc.'s trademark registration success rate?
Phoenix Biotechnology, Inc. has a 33% trademark registration rate, with 2 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.